HomeMedication lookupDrug classes › Weight management (GLP-1 agonists)
GLP-1 weight management

Weight management (GLP-1 agonists) and pharmacogenetics

Also known as: GLP-1 agonists, Incretin agonists, Weight loss medications

3 medications 5 brand products GLP1RGIPR

Why pharmacogenetics matter for weight management (glp-1 agonists)

GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) are the dominant new drug class for weight management and type 2 diabetes. They all work the same way: activating incretin receptors slows gastric emptying, increases satiety, and improves insulin response. Two SNPs explain a lot of the variation between patients. GLP1R rs10305420 affects every drug in the class. GIPR rs1800437 only matters for drugs that also activate GIP, which is tirzepatide and retatrutide.

The most actionable pharmacogenetic signal in this class is the GIPR Gln354 variant. If a patient stops tirzepatide because of nausea and carries that variant, switching to semaglutide is a logical next step. Semaglutide doesn't bind GIPR, so the variant doesn't apply.

Key genes in this class

Medications in this class with pharmacogenetic guidelines

Each link goes to the drug's full pharmacogenetics page with CPIC and FDA phenotype recommendations.

Brand products in the GLP-1 weight management class

Combined products and brand names for the medications above. Each links to a pharmacogenetic breakdown.

Which glp-1 weight management is right for your genetics?

This page covers the pharmacogenetics of weight management (glp-1 agonists) in general. A Gene2Rx report tells you how your personal genotype interacts with every drug on this page.

Get your report Look up a medication

Informational only, not medical advice. Pharmacogenetic guidelines describe population-level patterns that inform prescribing decisions. Never start, stop, or change a medication without talking to your prescribing clinician.

Get Your Report Now
Ready in One Minute